MedTrace Logo

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

NCT02388295 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2017-09-25

Study results available
· View outcomes & findings →

Summary

AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

Conditions

  • Multiple System Atrophy, MSA

Interventions

DRUG

AZD3241

Drug: AZD3241 administered for 12 weeks orally as a tablet.

DRUG

Placebo

Placebo to match AZD3241 administered for 12 weeks orally as a tablet.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-27
Primary Completion
2016-09-19
Completion
2016-09-19

Countries

  • United States
  • Austria
  • Finland
  • France
  • Italy
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388295 on ClinicalTrials.gov